Abstract Details
|
Edoardo Malfatti, MD
(APHP, Inserm U955, Université Paris Est)
PRESENTER |
Dr. Malfatti has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Spark therapeutics. Dr. Malfatti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. The institution of Dr. Malfatti has received research support from AFM. The institution of Dr. Malfatti has received research support from Spark Therapeutics. The institution of Dr. Malfatti has received research support from AFM. The institution of Dr. Malfatti has received research support from ANR. |
| Marcelo Chaves (Merck Serono Argentina) | No disclosure on file |
| No disclosure on file | |
| Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna) | Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB). |
| No disclosure on file | |
| Michel Fardeau, MD | No disclosure on file |
| No disclosure on file |